Alzheimer's Disease Genetics Consortium

Alzheimer's Disease Genetics Consortium
Name	Alzheimer's Disease Genetics Consortium
Abbreviation	ADGC
Formation	2008
Type	Consortium
Headquarters	United States
Parent organization	National Institute on Aging

Alzheimer's Disease Genetics Consortium The Alzheimer's Disease Genetics Consortium is a collaborative research initiative focused on identifying genetic risk factors for late-onset Alzheimer's disease through large-scale genomic studies. The consortium brings together cohorts, investigators, and resources from institutions such as the National Institute on Aging, National Institutes of Health, University of Pittsburgh, Mayo Clinic, and University of Washington to perform meta-analyses, genome-wide association studies, and replication efforts. Its work intersects with investigators associated with projects like the Alzheimer's Disease Neuroimaging Initiative, the Framingham Heart Study, and the Rotterdam Study to integrate genetic, clinical, and biomarker data.

Overview

The consortium aggregates case-control and cohort data from academic centers including Columbia University, Harvard Medical School, Johns Hopkins University, Washington University in St. Louis, University of California, San Francisco, and University College London to increase statistical power for detecting common and rare variants. It leverages genotyping platforms used by groups at Broad Institute, Wellcome Trust Sanger Institute, and Center for Genomic Regulation while coordinating bioinformatics pipelines similar to those developed at European Bioinformatics Institute and Stanford University. Membership has included investigators affiliated with awards such as the MacArthur Fellows Program, the Lasker Award, and the Breakthrough Prize in Life Sciences.

History and Formation

The consortium was formed in the late 2000s as part of a response by funders like the National Institute on Aging, Alzheimer's Association, and international partners including the Medical Research Council (United Kingdom) to the growing need for harmonized genetic datasets after early genome-wide association studies involving groups at deCODE genetics, Genentech, and GlaxoSmithKline. Key founding investigators had prior collaborations with centers such as Massachusetts General Hospital, University of California, Los Angeles, Mayo Clinic Arizona, and University of Toronto. The formation paralleled other large consortia like the 1000 Genomes Project and efforts by the International HapMap Project to standardize variant calling and imputation strategies.

Research Objectives and Activities

Primary objectives include discovery of risk loci for late-onset Alzheimer's disease through meta-analysis, fine-mapping of associated regions, and identification of rare variant contributions using sequencing platforms pioneered at Broad Institute and Sanger Institute. Activities encompass coordinating case ascertainment from longitudinal cohorts such as the Religious Orders Study, Rush Memory and Aging Project, and the Baltimore Longitudinal Study of Aging; harmonizing phenotypes with efforts like the National Alzheimer's Coordinating Center; and integrating molecular data types from the Human Genome Project-era resources to modern multi-omics frameworks used at Cold Spring Harbor Laboratory and EMBL. The consortium also develops statistical methods drawing on work from scholars at University of Michigan, University of Chicago, and University of California, San Diego.

Major Studies and Findings

ADGC-led meta-analyses have contributed to identification and replication of susceptibility loci beyond APOE clusters, implicating genes and regions linked to lipid metabolism, immune response, and endocytosis with overlap to findings reported by teams at Harvard T.H. Chan School of Public Health and University of Cambridge. Major publications have described novel loci that were later explored in functional studies at Broad Institute, Salk Institute, and Mount Sinai Health System. The consortium’s datasets have supported polygenic risk score development evaluated alongside cohorts such as UK Biobank and All of Us Research Program, and have informed cross-disease genetic analyses involving Parkinson's disease, amyotrophic lateral sclerosis, and stroke consortia. Collaborative sequencing efforts have tied into projects at NIH Intramural Research Program and commercial partners like Illumina for dense genotyping and rare-variant discovery.

Collaboration and Funding

Funding and collaboration networks include federal funders (notably National Institute on Aging and National Institutes of Health), non-profit organizations such as the Alzheimer's Association, and academic institutions including Yale School of Medicine, Duke University School of Medicine, and University of California, Irvine. International partnerships have involved the European Commission-funded initiatives and agencies like the Wellcome Trust, with data sharing agreements modeled on governance used by the Global Alliance for Genomics and Health. Technical partnerships with groups at Broad Institute, Sanger Institute, and Illumina provide genotyping and sequencing capacity, while statistical genetics expertise has been contributed by labs at University of Oxford, University of Edinburgh, and Karolinska Institutet.

Impact on Alzheimer's Research and Policy

The consortium’s aggregate findings have influenced biomarker research at centers such as Mayo Clinic and trial design considerations for pharmaceutical entities including Biogen, Eli Lilly and Company, and Roche. Its genetic discoveries informed risk stratification approaches used by investigators at Massachusetts General Hospital and policy discussions in advisory bodies tied to National Institutes of Health and the Alzheimer's Association. Cross-consortium data sharing practices contributed to standards adopted by projects like the Global Alzheimer's Association Interactive Network and helped shape translational priorities emphasized in strategic plans from the National Institute on Aging and major research funders.

Category:Genetics research consortia Category:Alzheimer's disease research